Abstract Accurate distant metastasis (DM) prediction is critical for risk stratification and effective treatment decisions in breast cancer (BC). Many prognostic markers/models based on tissue marker studies are continually emerging using conventional statistical approaches analysing complex/dimensional data association with DM/ poor prognosis. However, few of them have fulfilled satisfactory evidences for clinical application. This study aimed at building DM risk assessment algorithm for BC patients. A well-characterised series of early invasive primary operable BC (n = 1902), with immunohistochemical expression of a panel of biomarkers (n = 31) formed the material of this study. Decision tree algorithm was computed using WEKA software, utilising quantitative biomarkers' expression and the absence/presence of distant metastases. Fifteen biomarkers were significantly associated with DM, with six temporal subgroups characterised based on time to development of DM ranging from \1 to [15 years of follow-up. Of these 15 biomarkers, 10 had a significant expression pattern where Ki67LI, HER2, p53, N-cadherin, P-cadherin, PIK3CA and TOMM34 showed significantly higher expressions with earlier development of DM. In contrast, higher expressions of ER, PR and BCL2 were associated with delayed occurrence of DM. DM prediction algorithm was built utilising cases informative for the 15 significant markers. Four risk groups of patients were characterised. Three markers p53, HER2 and BCL2 predicted the probability of DM, based on softwaregenerated cut-offs, with a precision rate of 81.1 % for positive predictive value and 77.3 %, for the negative predictive value. This algorithm reiterates the reported prognostic values of these three markers and underscores their central biological role in BC progression. Further independent validation of this pruned panel of biomarkers is therefore warranted.
Introduction
Distant recurrence is the major cause of cancer-related deaths in breast cancer (BC) patients [1] . For cancer cells to successfully colonise a secondary site, they have to fulfil specific prerequisites to overcome the vast stresses throughout the metastatic cascade [2] . Collectively, the success of the metastatic process results from integration and contribution of complex molecular pathways controlling cellular proliferation, survival, metabolism, invasion and migration [3] .
Accuracy in BC prognosis/prediction, particularly distant recurrence risk assessment, is critical for accurate patients' stratification and effective treatment decisionmaking. Many prognostic markers and models based on tissue marker studies are continually emerging; however, very few of them have fulfilled satisfactory evidence for clinical application. Poor study design and misleading statistical analyses have been proposed as to explain discrepancies in research studies generating relevant clinically useful prognostic markers [4] . Mining large datasets regarding the expression patterns of a large number of biomarkers and clinical variables requires stringent statistical approaches to derive robust conclusions. Decision tree is an approach followed to automatically learn, through machine learning, to recognise complex patterns and illustrate relations between observed variables to make intelligent decisions. Therefore, decision tree algorithms could help improving our basic understanding of cancer development and progression [5] which can be used to assist the classification of BC cases by sorting them based on feature or attribute values (e.g. tissue marker expression). Each node in a decision tree represents a feature in a case to be classified, and each branch represents a value that the node can assume. Cases are classified starting at the root node and sorted based on their feature values [6] .
Perhaps the most common algorithm in literature for building decision trees is the C4.5 developed by Ross Quinlan. C4.5 is a statistical classifier system which uses the concept of information gain to make a tree of classificatory decisions with respect to a previously chosen target classification (e.g. distant recurrence). Each attribute of the data can be used to make a decision that splits the data into smaller subsets [7] . These outputs are then expressed as models, in the form of decision trees or sets of if-then rules, which can be used to classify new cases, with an emphasis on making the models understandable as well as accurate. In general, it is often possible to prune a decision tree to obtain a simpler and more accurate tree [6, 8] .
The aims of this study are to explore biomarkers of greatest impact on distant metastasis (DM) development in BC patients and their combinatorial behavioural expression patterns, and to build a decision tree algorithm for predictive tissue markers of DM which could be used, following validation, in newly diagnosed BC cases.
Materials and methods

Patients and tumours
This study was based on a well-characterised cohort of early stage (I-III) primary operable invasive BC (n = 1902) from patients enrolled into the Nottingham Tenovus Primary Breast Carcinoma Series between 1987 and 1998, and managed in accordance to a uniform protocol and has been comprehensively studied with a broad range of markers [9, 10] . During the follow-up time within this series, distant recurrence had developed in 578/1902 cases (30 %). The median time to DM was 128 months (range 4-247 months).
This study included 31 biomarkers of clinical and biological relevance to BC tumourigenesis and progression [9, 11] . These were hormone receptors [ [12, 13] , in addition to five markers/proteins encoded by five transcripts/genes significantly expressed between metastatic and non-metastatic BC (TOMM34, ZFN22, KRT23, ST8SIA6, and chromogranin-A). These latter markers resulted from ANN of analysis of cDNA expression data of 128 primary invasive frozen BC samples from the Nottingham Tenovus Primary Breast Carcinoma series previously studied using gene expression profiling (GEP) [14] . This approach stratified the transcripts on their ability to classify samples based on the occurrence of DM (n = 35) compared with those without DM (n = 93), as previously described [15, 16] . These five proteins are encoded by genes/transcripts' data analysed by artificial neuronal network. These genes were amongst the top 40 differentially expressed genes between metastatic and non-metastatic cases. This research was approved by Nottingham Research Ethics Committee 2 under the title of ''Development of a molecular genetic classification of breast cancer''.
Immunohistochemistry (IHC)
Four-lm sections were cut from paraffin-processed block of previously prepared TMAs and mounted on Superfrost slides (Surgipath). MIB1 expression was determined using full face FFPE breast tissue sections as previously described [17] . Tissue sections were deparaffinised in xylene (Genta Medica, York, UK), rehydrated in descending series of ethanol, 10 s each. Heat-induced retrieval of antigen epitopes was carried out using microwave treatment of slides in 10 mM sodium citrate buffer (pH 6.0) for 20 min. Slides were then incubated primary antibody in optimal working dilution ( Table 1 ). Secondary detection system was NovoLink TM Polymer Detection System (Leica, RE7150-K). Reaction was visualised using freshly prepared filtered solution of 3-3 0 Diaminobenzidine tetrahydrochloride (DAB, Dako, K3468). Counterstaining was performed with Mayer's haematoxylin (DAKO, AR106) for 6 min. Sections were dehydrated in alcohol, cleared in xylene and coverslipped using DPX mounting medium (BDH, Poole, UK).
Assessment of IHC staining
Slides were scanned as high resolution digital images (0.45 lm/pixel) using a NanoZoomer slide scanner (Hamamatsu Photonics, Welwyn Garden City, UK) and accessed using a web-based interface (Distiller, SlidePath Ltd, Dublin, Ireland). TMA cores were scored at 920 magnification using a minimum of 24 high-resolution screen (1920 9 1080).
Scoring of IHC staining of markers was performed using the modified H-score method [18] , except MIB1LI and BCL2 which were scored as the percentage of expression. All sections were scored without prior knowledge of the patients' pathologic or outcome data.
Statistical analysis
To establish a set of rules to determine to which group; presence or absence of DM, a patient is more likely to be assigned using its variables' values; WEKA software was used to compute the decision tree algorithm C4.5. Wilcoxon test, a non-parametric version of t test, was used to specify those markers appearing to behave differently in the two groups of patients. Results were validated using univariate Cox regression analysis. A p value \0.05 (two-tailed) was considered significant. Box plots were organised to visualise the differential distribution of each marker between those cases with metastatic disease from those without.
Results
Box plots for the distribution of all the 31 markers' expression within the studied series with relevance to the presence or absence of distant metastases are summarised in Fig. 1a . According to these plots, the variable distribution of markers within both patients' subsets can be inferred. For instance, the H-score of PR expression for 95 % of cases with DM ranges from ''0-150'', median 5, compared with ''0-200'', median 90 in cases with no DM.
To test those markers which were the drivers of the two groups, Wilcoxon test and univariate Cox regression analysis were performed. This resulted in a panel consisting of 15 biomarkers being significantly associated with distant recurrence (p \ 0.001). These markers were Ki67/MIB1LI, ER, PR, HER2, EGFR, p53, BCL2, N-cadherin, P-cadherin, PIK3CA, pSTAT3 nuclear expression, TOMM34, ZFN22, CD44 and Ck5/6. Table 2 displays these markers and the functional group under which they could be classified. Figure 1b displays box plots showing differential expression levels of this panel within metastatic versus nonmetastatic groups of the studied series. As these plots display, variable distribution of different markers between the two groups could be appreciated. For instance, the H-score of BCL2 expression for 95 % of cases with distant recurrence lies between ''0-75'', median 50, compared with ''0-100'', median 70 in cases with no distant recurrence.
Biomarker expression pattern and time to distant metastasis
Based on time to development of DM in cases where distant recurrence occurred (n = 578 patients), six temporal subgroups were characterised, which ranged from less than 1 year of follow-up to more than 15 years. These were (1) \1 year (n = 50), (2) between 1 and 2 years (n = 102), (3) [2 up to 5 years (n = 201), (4) [5 up to 10 years (n = 155), (5) [10 up to 15 years (n = 56) and (6) [than 15 years (n = 14). Box blots were constructed to depict the expression pattern of the 15 biomarker panel significantly associated with DM within these temporal subgroups, Fig. 2 . According to box plots of these metastatic subgroups, 10 markers had a significant expression pattern with respect to time of developing DM. However, the remaining five markers did not show this temporal relation with occurrence of DM.
Markers with significant expression trend within groups of time to distant recurrence Within this group of markers, Ki67/MIB1LI, HER2, p53, N-cadherin, P-cadherin, PIK3CA and TOMM34 showed characteristic pattern of differential expression between the six subgroups, where higher expression values were associated with significantly earlier development of distant recurrence and vice versa. For PIK3CA, the expression values were very high for those cases that developed earlier DM (mean H-sore = 210 in those developed DM in less than 1 year compared with 130 in those developed DM [10 years up to 15 years). In contrast, higher expression values of ER, PR and BCL2, were observed to be associated with delayed occurrence of DM.
Markers with no observed expression trend within the time to distant recurrence period
The remaining markers, however, (i.e. EGFR, phospho-STAT3, ZFN22, CD44 and CK5/6), did not show an evident behavioural/differential trend in their expression with relevance to the time to development of DM in the six metastatic subgroups.
Decision tree-calculated metastasis prediction algorithm
To build a distant recurrence risk assessment algorithm for BC patients, decision trees were computed. For the purpose of robustness, only cases with complete values for all biomarkers were used to compute the decision tree. The number of informative cases available for the 15 significant markers was 176 cases, which constituted a test set for building a decision tree algorithm for metastatic recurrence prediction. DM had developed in 64 (36.3 %) cases, with the remaining 112 (63.7 %) cases remaining DM free throughout the period of follow-up. The input data for WEKA software were the expression data of these 15 markers, entered as continuous data ''H-score or % expression'', and the metastatic status (Yes/No), with minimum number of cases in each branch to be equal to or more than 4. The resulting tree is as illustrated in Fig. 3 .
According to the tree, four groups of patients were characterised, based on the expression of three markers p53, HER2 and BCL2, which were able to predict the probability of DM in the test set. Cut-off points for these three markers were automatically set by the software. Table 3 displays these groups and the number of correctly classified and misclassified cases in each of group.
This ability of this algorithm to classify patients on the basis of probability of DM (i.e. DM Yes and DM No) was significantly associated with tumour size, tumour grade, number of positive axillary lymph nodes and BC molecular subtype as assessed by IHC [19] . Although associations with axillary nodal stage and lymphovascular invasion (LVI) did not reach statistical significance, more proportions of cases with C4 positive axillary nodes experienced DM more than those with node negative disease (30 % versus 13.5 %, respectively). Supplementary The precision rate of this algorithm in predicting DM was evaluated using the positive predictive value (PPV) and the negative predictive value (NPV) [20] . For this algorithm, the PPV = 26/32 = 81.1 %, and the NPV = 150/194 = 77.3 %.
Discussion
Within the studied series, DM had developed in 30 % of cases during the period of follow-up and the outcome of this group was markedly reduced compared to patients who did not develop DM (5-year survival rate was 58 % compared to 98 %, respectively). This significant decline in patients' survival is, to a large extent, attributable to the biological differences in tumours with metastatic potential from those without. Therefore, the molecular factors driving growth and differentiation pathways in tumours with metastases were scrutinised to explore their relative contribution in their non-metastatic tumour counterparts.
For this purpose, the expression pattern of 31 biomarkers with close relevance to BC biology and progression was studied with relevance to the occurrence of DM. Based on their distributions as continuous variables, many of the studied markers displayed variable expression within both patients' subsets with and without DM, respectively. However, a panel formed of fifteen markers was significantly associated with the occurrence of DM.
Functional categories within this biomarker panel revealed that they belonged to molecular pathways responsible for carcinogenesis and cancer progression including hormonal receptors (ER, PR), epidermal growth factor receptor family members (EGFR, HER2), tumour growth fraction as assessed by MIBL1, tumour suppressor p53, anti-apoptotic BCL2, cell adhesion molecules (N-cadherin, P-cadherin), signalling pathways and transcription factors (PIK3CA, pSTAT3 and ZNF22), basal Ck14, TOMM34 and CD44.
In meta-analysis of publicly available BC GEP studies, Wirapati and colleagues showed that the key biological drivers in nine prognostic signatures were proliferationrelated genes, in addition to ER signalling and HER2 amplification [21] . The current IHC marker panel shared ER, PR, HER2 and proliferative fraction as major drivers of progression with GEP studies [21] . Additionally, p53 and BCL2 were among the major contributors of DM in the IHC panel. Inactive TP53, as assessed by positive p53 protein expression, disturbs the functional braking and emergency cell cycle arrest in genetically damaged cells leading ultimately to cell cycle progression [22] . On the other hand, BCL2 is a cellular pro-survival molecule that protects transformed cells from apoptotic cell death. Therefore, from functional point of view, p53 and BCL2 which were more expressed in metastatic cases, lead to enhanced cell proliferation, through cell cycle progression and cell immortalisation [23] .
The expression of basal/myoepithelial markers has been previously reported to contribute to the identification of a subset of BC characterised by poor outcome, the basal-like All markers were scored using H-score (i.e. ranged from 0 to 300), except MIB1LI and BCL2 which were scored as percentages (i.e. ranged from 0 to 100) subtype [24] . In the current IHC panel, two markers could be assigned into this category of markers: EGFR and Ck14. These results support recommendations of using these two makers, beside ER, PR and HER2 negativity, as additional surrogates in characterising BCs with basal phenotype [25] . Moreover, the roles played by PIK3CA in BC progression through its downstream effectors, especially through driving an epithelial-to-mesenchymal transition program (EMT) with upregulation of N-cadherin and P-cadherin, have been reported in the same series [26, 27] , as well as in others [28] . Metastatic recurrence developed in these patients with primary BC over a time schedule ranged from 4 months to more than 15 years. Ten markers of the IHC biomarker panel displayed differential expression patterns within the temporal groups of time to DM. These include ER, PR, HER2, MIB1LI, p53, BCL2, N-cadherin, P-cadherin, PIK3CA and TOMM34. However, the remaining five markers did not show this sort of trend. Markers of poor prognostic impact [MIB1LI, HER2, p53, N-cadherin, P-cadherin, PIK3CA and TOMM34] were more expressed in cases where DM had manifested earlier, while less Circles represent the markers in the algorithm (p53, HER2 and BCL2). Rectangles represent feature value tested (DM); Zero = No DM, One = Yes DM and numbers represent subsets of patients correctly classified and misclassified, respectively. Branches emerging from each marker are levels (H-score for p53 and HER2, and percentage of BCL2) of expression below or above which a specific case is to be classified into either zero or one expression was observed with prolonged metastasis-free intervals. The reverse was true for biomarkers of good prognostic impact [ER, PR and BCL2]. These findings could be interpreted in view of the concept of tumour dormancy, in which disseminated cancer cells leaving the primary tumour stay dormant for variable periods of times in another anatomical niche that could extend into many years. During this dormancy stage, cells may remain quiescent or form clinically undetectable micrometastases. Entering of these dormant cells or micrometastatic nodules into an overt progressive growth phase leads to the commencement of clinically detectable metastasis. The length of dormancy periods has been determined by balancing cell proliferation and apoptosis [29, 30] . More insight into the differentially expressed markers between early and late metastatic groups reveals, once again, that major drivers of BC progression, especially proliferation and apoptosis regulator, not only play major roles in emergence of recurrences but also in the time of their arousal.
Using the 15 IHC biomarker panel and decision tree, a probabilistic algorithm was computed to be applied for risk assessment of DM in BC patients. According to the resulting algorithm, four risk groups of patients were characterised. Expression levels of p53, HER2 and BCL2 at automatically-generated specific cut-off points were able to predict the probability of distant recurrence in the studied set with satisfactory precision rate 81.1 % PPV and 77.3 % NPV. Therefore, a tumour suppressor, an oncogene and an anti-apoptotic marker could be reliably used in DM risk prediction. In the root node of the decision tree, p53 expression was the first determinant, with distant recurrence expected in cases of high p53 (H-score [60) with HER2 or p53 high, low HER2 and low BCL2. However, low p53 alone or high p53, low HER2 and high BCL2 were associated with lower risk of DM. The ability of this probabilistic model in stratifying patients into DM risk groups was significantly associated with tumour size, grade, number of positive axillary lymph nodes and BC molecular subtype. Moreover, the model was significantly associated with both BCSS and metastasis-free interval, independent of other factors. This algorithm reiterates the documented prognostic values of these three markers and underscoring the central biological role played by each of these three markers in BC progression [31] [32] [33] . According to these results, this small or pruned panel of biomarkers could be used with acceptable success in distant recurrence prediction. However, its performance needs to be validated in an independent BC patient series especially on a prospective basis.
Conclusions
Metastatic recurrence in the studied series appears to result from contribution of a molecular biomarker panel controlling the major nodes in carcinogenic and progression pathways including hormonal receptors, growth factors, tumour suppressor, apoptotic regulator, cell adhesion apparatus and transcription factors. A predictive algorithm formed of p53, BCL2 and HER2 IHC expression was able to successfully predict the probability of distant recurrence, which requires independent validation. These findings affirm that metastasis is an inherent early cancer trait that could be predicted from the primary tumour biomarker expression profile. p53 and HER2 expression were assessed as H-scores, while BCL2 was assessed as % of expression
